Release Date: 2024-06-12

Immunotherapy in Acute Leukemias

Leylagul Kaynar (Author), Yasemin Ozgur (Author)

Release Date: 2024-06-12

Immunotherapeutic agents have made remarkable progress in the treatment of acute leukemia. CAR T cell therapy, particularly CD19 and BCMA-targeted CAR-T cells, has shown promising results with high response rates and long remission durations. However, these therapies can be challenging to manage and may present serious toxicities, requiring careful monitoring. Despite the challenges in AML [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inImmunotherapy in Human Cancers
    First Page61
    Last Page89
    DOIhttps://doi.org/10.69860/nobel.9786053359388.6
    Page Count29
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Immunotherapeutic agents have made remarkable progress in the treatment of acute leukemia. CAR T cell therapy, particularly CD19 and BCMA-targeted CAR-T cells, has shown promising results with high response rates and long remission durations. However, these therapies can be challenging to manage and may present serious toxicities, requiring careful monitoring. Despite the challenges in AML CAR-T cell therapy, new approaches targeting CD33, CD123, and other antigens hold potential for effective treatment options in these patients. In ALL, anti-CD19, anti-CD22 agents, and even CAR-T cell therapies have started to find their place in practical use. With these developments, the integration of immunotherapies into personalized treatment plans is beginning to open new horizons in leukemia treatment.

    Leylagul Kaynar (Author)
    MD, Professor, Istanbul Medipol University
    https://orcid.org/0000-0002-2035-9462
    3Prof. Dr. Leylagül KAYNAR Education: Erciyes University Medical Faculty (1994-2000) Internal Medicine Specialization Education in Erciyes University Department of Internal Medicine (2000-2005) Hematology Specialization Education in Erciyes University Hematology Department (2006-2010) Observer Doctor in Duke University Hematology Department (2011-2011) As a Hematology Specialist in Erciyes University (2010-2021) He is currently working as a hematology specialist at Istanbul Medipol University, Head of Hematology Department. (2021-… )

    Yasemin Ozgur (Author)
    MD, Assoc. Prof. Dr., Başaksehir Cam and Sakura City Hospital
    https://orcid.org/0000-0002-7112-4575
    3Associate professor Dr Yasemin Özgür Education: Istanbul university medical school (2001-2007) Conscription: Düzce Gümüsova 112 emergency health services (2007-2009) Internal medicine specilization: Haydarpaşa education and research Hospital, Department of internal medicine (2009-2013) Conscription: Rize Recep Tayyip Erdoğan University, Education and Research Hospital, Department of Internal Medicine (2013-2016) Kartal City Hospital, Department of Internal Medicine (2016-2021) Internal medicine associate professor (04/04/2023) Hematology specilization: Başakşehir Cam and Sakura City Hospital (2021-2024)

    • Sophie Paczesny, Steven Z. Pavletic, Catherine M. Bollard; Introduction to a review series on emerging immunotherapies for hematologic diseases. Blood 2018; 131 (24): 2617–2620.

    • Catherine M. Bollard; Introduction to a review series on immunotherapies for nonmalignant hematologic diseases. Blood 2022; 139 (25): 3561.

    • Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018 Oct;14(10):857-872.

    • Brodsky RA. Warm Autoimmune Hemolytic Anemia. N Engl J Med. 2019 Aug 15;381(7):647-654.

    • Murakhovskaya I. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med. 2020 Dec 13;9(12):4034.

    • D. Shan, J. A. Ledbetter, and O. W. Press, “Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies,” Blood, vol. 91, no. 5, pp. 1644–1652, 1998.

    • Berentsen S, Tjonnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev. 2012;26(3):107–15.

    • Berentsen S, Barcellini W, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood (2020) 136(4):480–8.

    • Berentsen S, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925-2928.

    • Röth A, Barcellini W, D’Sa S, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334.

    • Röth A, Bommer M.; et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018 Oct 9;2(19):2543-2549.

    • Shanbhag S, Spivak J. Paroxysmal cold hemoglobinuria. Hematol Oncol Clin North Am. 2015 Jun;29(3):473-8.

    • Miano M et al: The diagnosis and treatment of aplastic anemia: a review. Int J Hematol. 101(6):527-35, 201525837779.

    • Young NS et al: Aplastic anemia. In: Hoffman R et al, eds: Hematology: Basic Principles and Practice. 7th ed. Elsevier; 2018:394-414.

    • Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3(23):3829–3866.

    • Ghanima W, Gernsheimer T, Kuter DJ. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood (2021) 137:2736–44.

    • Arnold DM, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25–33.

    • Nelson MH, Paulos CM. Novel immunotherapies for hematologic malignancies. Immunol Rev. 2015 Jan;263(1):90-105.

    • Garnett C, Apperley JF, Pavlů J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013 Dec;4(6):366-78.

    • Takeda J, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73(4):703-711.

    • Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014; 124(18):2804-2811.

    • Raina R, et al. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial. 2019 Feb;23(1):4-21.

    • Scully, M.; et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J. Thromb. Haemost. 2017, 15, 312–322.

    • Owattanapanich, W.; et al. Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis. Clin. Appl. Thromb. Hemost. 2019, 25.

    • Sukumar, S.; Lämmle, B.; Cataland, S.R. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J. Clin. Med. 2021, 10, 536.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!